Key market opportunities in oncology biosimilars include leveraging AI for streamlined clinical trials and precision medicine ...
Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...
Credit: Fresenius Kabi. Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion. The biosimilar received FDA approval on ...
Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...
The clock of the global pharmaceutical and biotech market is rapidly ticking toward the so-called "patent cliff." As patents ...
Boehringer Ingelheim has received the Food and Drug Administration’s blessing for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable ...
The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...
Yonhap News Agency on MSN
Celltrion launches biosimilar Avtozma in 3 European markets
Celltrion Inc., a major South Korean biopharmaceutical company, said Friday it has launched its biosimilar Avtozma for the ...
TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV ...
RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results